Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.

Autor:	Wendel SK; 1 Laboratory of Immunoregulation (LIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) , Baltimore, Maryland., Longosz AF; 2 Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland., Eshleman SH; 3 Department of Pathology, Johns Hopkins University School of Medicine , Baltimore, Maryland., Blankson JN; 2 Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland., Moore RD; 2 Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland., Keruly JC; 2 Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland., Quinn TC; 1 Laboratory of Immunoregulation (LIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) , Baltimore, Maryland.; 2 Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland., Laeyendecker O; 1 Laboratory of Immunoregulation (LIR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) , Baltimore, Maryland.; 2 Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland.
Jazyk:	angličtina
Zdroj:	AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2017 Apr; Vol. 33 (4), pp. 325-327. Date of Electronic Publication: 2017 Jan 11.
DOI:	10.1089/AID.2016.0105
Abstrakt:	We analyzed the impact of HIV viral load on the performance of a limiting antigen avidity enzyme immunoassay (LAg-Avidity assay) and determined if this assay could be used to identify viral breakthrough. Three groups of samples were tested: (1) 18 individuals (30 samples) previously identified as elite suppressors; (2) 18 individuals (72 samples) who were continually suppressed on antiretroviral treatment (ART) with 1 sample before and 2-6 samples (one/year) after ART initiation; and (3) 20 individuals (179 samples) on ART who had evidence of viral breakthrough (>400 copies/ml) with subsequent viral suppression. Elite suppressors had the lowest LAg-Avidity assay values. Among those who were continually suppressed on ART, 83% (15/18) had LAg-Avidity assay values that decreased over time. Although the LAg-Avidity assay on a single sample cannot identify when a viral breakthrough occurs, paired longitudinal samples could identify viral breakthrough (sensitivity: 65%, specificity: 84%).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu